About Array BioPharma
Array BioPharma Inc. (Array) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In addition, pharmaceutical and biotechnology companies collaborate with the Company to discover and develop drug candidates – more... across a range of therapeutic areas. The Company has seven wholly owned programs in its development pipeline: ARRY-403, a glucokinase activator for Type 2 diabetes; ARRY-162, a MEK inhibitor for rheumatoid arthritis and cancer; ARRY-380, an ErbB-2 inhibitor for breast cancer; ARRY-520, a KSP inhibitor for acute myeloid leukemia and multiple myeloma; ARRY-614, a p38/Tie 2 dual inhibitor for myelodysplastic syndrome; ARRY-543, an ErbB family (ErbB-2 / EGFR) inhibitor for solid tumors, and ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications.
(Source: 10-K) – less – More from ZoomInfo »
Array BioPharma Employer Reviews
Array BioPharma
A company of dynamic science driven people with great energy and passion
Manager, Translational Medicine (Former Employee), Boulder, CO – May 2, 2012
Array BioPharma
Small company with a core group of very good people
Senior Group Leader (Former Employee), Boulder, CO – April 15, 2012
Working at Array BioPharma
